研究单位：[1]Hangzhou Endonom Medtech Co., Ltd.[2]Beijing Anzhen Hospital, Capital Medical University,Beijing,China[3]Chinese PLA Gencral Hosptial,Beijing,China[4]The First Hospital of Jilin University,Changchun,China[5]Xiangya Hospital of Central South University,Changsha,China[6]West China Hospital of Sichuan University,Chengdu,China[7]Guangdong Provincial Hospital of Traditional Chinese Medicine,Guangzhou,China[8]The First Affiliated Hospital ,Sun Yat-sen University,Guangzhou,China[9]The First Affiliated Hospital of Harbin Medical University,Harbin,China[10]Shandong Provincial Hospital,Jinan,China[11]The First People's Hospital of Yunnan Province,Kunming,China[12]The Second Affiliated Hospital Of Nanchang University,Nanchang,China[13]Nanjing First Hospital,Nanjing,China[14]The First Affiliated Hospital of Nanjing Medical University,Nanjing,China[15]The Affiliated Hospital Of Qingdao University,Qingdao,China[16]Shanghai Chest Hospital,Shanghai,China[17]Zhongshan Hospital, Fudan University,Shanghai,China[18]The First Affiliated Hospital of China Medical University,Shenyang,China[19]Xiamen Cardiovascular Hospital,Xiamen,China[20]The First Affiliated Hospital of PLA Air Force Military Medical University,Xian,China[21]First Affiliated Hospital of Zhengzhou University,Zhengzhou,China
研究目的：
A prospective ,Multiple Center Study About the Safety and Efficacy of WeFlow-Tribranch Embedded Aortic Triple-branch Arch Stent Graft System manufactured by EndoNom Medtech (Hangzhou) Co., Ltd. for true/pseudo aortic arch aneurysms and ulcers involving aortic arch . (GENIUS Study)
